Is Tesamorelin safe?
Well-StudiedSide effects, risks, and safety considerations based on available research.
Research status
Tesamorelin has a relatively strong evidence base including clinical trials in humans. This does not mean it is without risks, but its safety profile is better characterized than many other peptides.
Known concerns & side effects
- ⚠FDA-approved only for HIV-associated lipodystrophy — off-label use for anti-aging or body composition is not approved
- ⚠common side effects include joint pain (arthralgia), mild fluid retention (edema), and injection-site redness
- ⚠raises IGF-1 levels — periodic IGF-1 monitoring is essential; elevated IGF-1 is associated with theoretical cancer risk
- ⚠contraindicated with active malignancy or history of pituitary tumor, head radiation, or surgery
- ⚠mild elevations in fasting glucose and A1c have been observed — metabolic monitoring required
- ⚠not appropriate during pregnancy
- ⚠prescription-only in most jurisdictions; off-label compounded versions vary widely in quality
Use caution with
Relevant safety research
FDA approval: Egrifta WR (tesamorelin F8 formulation)
Finding: Bioequivalence study demonstrated similar efficacy and safety of the new F8 formulation vs the original Egrifta SV. Improved reconstitution and smaller injection volume confirmed. FDA approved March 25, 2025.
Limitation: Regulatory approval study focused on bioequivalence, not additional efficacy endpoints beyond those established in original pivotal trials.
See all 3 studies on the full Tesamorelin profile.
Frequently asked questions
Is tesamorelin the same as HGH?
No. Tesamorelin is a GHRH analog — it stimulates your own pituitary gland to produce growth hormone naturally. Exogenous HGH bypasses this system entirely. Because tesamorelin works through the body's feedback loops, GH release remains pulsatile and self-regulated, which is considered safer than direct HGH injection.
Can tesamorelin be used for weight loss without HIV?
Its FDA approval is specifically for HIV-associated lipodystrophy. Off-label use for general weight loss or anti-aging is common in longevity clinics but is not supported by randomized controlled trials in non-HIV populations. A physician must prescribe it for any indication.
What is Egrifta WR?
Egrifta WR is a newer formulation of tesamorelin approved by the FDA in March 2025. It provides the same efficacy as the original Egrifta SV but with a simplified reconstitution process and weekly rather than daily preparation, improving adherence.
How is tesamorelin different from CJC-1295?
Both are GHRH analogs that stimulate GH release, but tesamorelin is FDA-approved with extensive clinical trial data, while CJC-1295 is a research chemical without FDA approval for any use. Tesamorelin is the 44-amino-acid full GHRH sequence; CJC-1295 is a modified 30-amino-acid fragment. Tesamorelin's evidence base in humans is considerably stronger.
Full Tesamorelin Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.